NUVL

NUVL

USD

Nuvalent Inc. Class A Common Stock

$92.690-1.560 (-1.655%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$94.250

最高价

$95.225

最低价

$92.075

成交量

0.28M

公司基本面

市值

6.7B

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

0.46M

交易所

NMS

货币

USD

52周价格范围

最低价 $55.535当前价 $92.690最高价 $104.9

相关新闻

PR Newswire

Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...

查看更多
Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer
Analyst Upgrades

UBS Maintains Buy on Nuvalent, Raises Price Target to $132

UBS analyst David Dai maintains Nuvalent with a Buy and raises the price target from $114 to $132.

查看更多
UBS Maintains Buy on Nuvalent, Raises Price Target to $132
PR Newswire

Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...

查看更多
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results
Analyst Upgrades

Piper Sandler Maintains Overweight on Nuvalent, Raises Price Target to $128

Piper Sandler analyst Kelsey Goodwin maintains Nuvalent with a Overweight and raises the price target from $112 to $128.

查看更多
Piper Sandler Maintains Overweight on Nuvalent, Raises Price Target to $128